Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double‐Blind, Phase 3 Trial in China
Arthritis & Rheumatology · 2025-12 · 77 (12) · 1757-1766
DOI: 10.1002/art.43261 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Arthritis & Rheumatology, online erschienen am 08.09.2025. Verfasst von Jia Sun und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Zhujiang Hospital of Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Gout, Febuxostat, Gout Suppressants, Triazoles. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
Dotinurad is a selective urate reabsorption inhibitor that reduces serum urate levels. We compared the efficacy and safety of dotinurad with febuxostat in Chinese patients with gout.
Methods
This phase 3, multicenter, randomized, double‐blind, parallel‐group study randomly allocated (1:1) eligible patients with gout to receive oral dotinurad or febuxostat. The primary end point was the responder rate (proportion of patients achieving serum urate levels ≤6.0 mg/dL) at week 24 in the full analysis set (FAS) to demonstrate superiority of dotinurad 4 mg/day to febuxostat 40 mg/day. The secondary end points included the responder rate at week 12 to show the noninferiority of dotinurad 2 mg/day to febuxostat 40 mg/day. Treatment‐emergent adverse events (TEAEs) were also recorded.
Results
A total of 451 patients were randomized, and 441 were included in the FAS. Baseline characteristics were well balanced between treatment groups. The responder rate at week 24 was significantly higher for dotinurad 4 mg/day versus febuxostat 40 mg/day (73.6% vs 38.1%; adjusted difference 35.9% [95% confidence interval (CI) 27.4%–44.4%]; P < 0.0001), and at week 12, dotinurad 2 mg/day was noninferior to febuxostat 40 mg/day (55.5% vs 50.5%; adjusted difference 5.2% [95% CI −3.7% to 14.2%]). Incidences of TEAEs in the dotinurad and febuxostat groups were similar.
Conclusion
Dotinurad 4 mg/day was superior to febuxostat 40 mg/day in achieving serum urate levels ≤6.0 mg/dL at week 24 and was well tolerated in Chinese patients with gout.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Zhujiang Hospital of Southern Medical University, Guangzhou, China.
- Department of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing, China.
- Department of Rheumatology, Beijing Hospital, National Centre of Gerontology, Beijing, China.
- Department of Rheumatology, Foshan First People's Hospital, Foshan, China.
- Department of Rheumatology, Jiangxi Pingxiang People's Hospital, Pingxiang, China.
- Department of Rheumatology, Shenzhen People's Hospital, Shenzhen, Guangdong, China.
ORCID-Profile: Changgui Li, Zhuoli Zhang
Zitieren
APA
Sun, J., Wang, Y., Cheng, Y., Guo, D., Hu, J., Liu, D., Gao, Z., Li, C., Lu, Y., Kong, X., Liu, Y., Jiang, Z., Yi, B., Zhang, H., Xu, B., Yu, S., Kokan, R., Ishikawa, K., Kawakatsu, M., & Zhang, Z. (2025). Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double‐Blind, Phase 3 Trial in China. Arthritis & Rheumatology, 77(12), 1757-1766. https://doi.org/10.1002/art.43261
Vancouver
Sun J, Wang Y, Cheng Y, Guo D, Hu J, Liu D, et al. Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double‐Blind, Phase 3 Trial in China. Arthritis & Rheumatology. 2025;77(12):1757-1766. doi:10.1002/art.43261
BibTeX
@article{Sun2025,
author = {Sun, Jia and Wang, Yu and Cheng, Yongjing and Guo, Dongmei and Hu, Jiankang and Liu, Dongzhou and Gao, Zhengnan and Li, Changgui and Lu, Yibing and Kong, Xiaodan and Liu, Yu and Jiang, Zhenyu and Yi, Bin and Zhang, Hongfeng and Xu, Baijie and Yu, Shihao and Kokan, Rieko and Ishikawa, Kohei and Kawakatsu, Mikiko and Zhang, Zhuoli},
title = {Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double‐Blind, Phase 3 Trial in China},
journal = {Arthritis & Rheumatology},
year = {2025},
volume = {77},
number = {12},
pages = {1757--1766},
doi = {10.1002/art.43261}
}
EUVIMED